Gut microbiome functional genomics and PBPK modeling: a systems framework for precision therapeutics

Jeyavelkumaran, Renukadevi, Saravanan, Mridula Dhanapal, Keerthivasan, Nimithasree
Folia Microbiologica · Springer Nature · 2026-11-19 · DOI: 10.1007/s12223-026-01641-9

Аннотация

The gut microbiome is increasingly recognized as an important determinant of interindividual variability in the disposition and response to pharmaceuticals, nutraceuticals, and dietary bioactives. Conventional microbiome profiling based primarily on taxonomic composition provides limited mechanistic insight into these effects, whereas functional genomics and multi-omics approaches enable characterization of microbial genes, enzymes, pathways, and metabolites involved in xenobiotic biotransformation. This review examines the integration of gut microbiome functional genomics with physiologically based pharmacokinetic (PBPK) modeling as a systems framework for precision therapeutics. Particular emphasis is placed on translating microbial gene–enzyme–metabolite relationships and experimentally characterized biotransformation kinetics into quantitative PBPK parameters. Metagenomics, metatranscriptomics, metaproteomics, and metabolomics provide complementary information for resolving microbial metabolic potential and activity, while genome-scale and community metabolic models can identify candidate pathways for xenobiotic transformation and metabolite production. Microbiome-aware PBPK approaches may incorporate microbial biotransformation, metabolite formation, gastrointestinal transit, absorption, and temporal functional variability. Whether these additions improve exposure predictions requires evaluation against conventional PBPK models using independent pharmacokinetic datasets.Artificial intelligence and machine learning may further support functional feature identification and hybrid PBPK modeling, provided that predictions remain biologically interpretable and experimentally validated. Despite its potential, clinical translation is constrained by limited standardized kinetic data, microbiome variability, incomplete functional annotation, and insufficient prospective validation. Integrating validated microbial functional information with mechanistic PBPK modeling may ultimately provide a quantitative basis for microbiome-informed prediction of drug and nutraceutical exposure and advance individualized therapeutic strategies. Graphical Abstract

Читать у издателя →

Похожие статьи